ENDV (Endonovo Therapeutics) EBITDA Margin %: 0.00% (As of Jun. 2025)


What is Endonovo Therapeutics EBITDA Margin %?

Endonovo Therapeutics ENDV EBITDA Margin % is 0.00% as of Jun. 2025. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Endonovo Therapeutics ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Endonovo Therapeutics's EBITDA for the three months ended in Jun. 2025 was $-0.25 Mil. Endonovo Therapeutics's Revenue for the three months ended in Jun. 2025 was $0.00 Mil. Therefore, Endonovo Therapeutics's EBITDA margin for the quarter that ended in Jun. 2025 was 0.00%.

Endonovo Therapeutics  (OTCPK:ENDV) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Endonovo Therapeutics EBITDA Margin % Related Terms

Endonovo Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Endonovo Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endonovo Therapeutics EBITDA Margin % Chart

Endonovo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,409.04 -2,075.34 -12,226.67 6,324.29 -9,410.00

Endonovo Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12,500.00 0.00 0.00 0.00 0.00

ENDV vs RGBP, IOBTQ, CNBX: EBITDA Margin % Comparison

For the Biotechnology subindustry, Endonovo Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endonovo Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's EBITDA Margin % falls into.


Endonovo Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Endonovo Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-0.941/0.01
=-9,410.00 %

Endonovo Therapeutics's EBITDA Margin % for the quarter that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-0.249/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Endonovo Therapeutics (ENDV) has a EBITDA Margin % of 0.00% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Endonovo Therapeutics and its competitors. According to the industry distribution chart, Endonovo Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is Endonovo Therapeutics' EBITDA Margin % too high?
Endonovo Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Endonovo Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Endonovo Therapeutics' EBITDA Margin % compare to RGBP and IOBTQ?
According to the Biotechnology industry distribution chart, Endonovo Therapeutics ranks #999999 out of 945 companies for EBITDA Margin %. This places Endonovo Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Endonovo Therapeutics and its competitors. Endonovo Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current EBITDA Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Endonovo Therapeutics Business Description

Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.